EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Safety of biliary drainage with 6‐mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY

Shota Harai iD, Susumu Hijioka iD, Reiko Yamada, Takeshi Ogura iD, Mitsuharu Fukasawa iD, Atsushi Okuda iD, Hideyuki Horike, Dai Inoue, Masanari Sekine, Yusuke Ishida iD, Takehiko Koga iD, Hidetoshi Kitamura und 8 weitere

Journal of Gastroenterology and Hepatology · 2024-07 · 39 (7) · 1442-1449

DOI: 10.1111/jgh.16524 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 29.02.2024. Verfasst von Shota Harai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Drainage, Pancreatic Neoplasms, Jaundice, Obstructive, Stents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Cancer Center Research and Development Fund, Japanese Foundation for Research and Promotion of Endoscopy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim The 10‐mm self‐expandable metal stent (SEMS) is the standard for endoscopic transpapillary biliary drainage before pancreatic cancer surgery. However, the efficacy of stents thinner than 10 mm has not been adequately validated. Therefore, we aimed to evaluate the safety of a 6‐mm fully covered SEMS (FCSEMS) for distal malignant biliary obstruction (DMBO) during preoperative chemotherapy for pancreatic cancer.

Methods

This was a single‐arm, multicenter, prospective phase II study of endoscopic transpapillary initial biliary drainage for DMBO before pancreatic cancer surgery. The primary endpoint was stent‐related adverse events, and the key secondary endpoint was the non‐recurrent biliary obstruction (non‐RBO) rate during the observation period for both resectable (R) and borderline resectable (BR) pancreatic cancers.

Results

The study enrolled 33 patients, among whom 32 received the study treatment. There were 23 and 9 cases of R and BR pancreatic cancers, respectively. The technical and clinical success rates were 97.0% and 90.1%, respectively. The stent‐related adverse event rate was 3.1% ( n = 1, acute pancreatitis) (95% confidential interval, 0.00–16.2), which met the criteria to be considered safe. The overall non‐RBO rate during the observation period (median 96 days) was 78.1% (82.6% and 66.7% for R and BR pancreatic cancer cases, respectively).

Conclusions

The 6‐mm FCSEMS is an extremely safe metallic stent with a low stent‐related adverse event rate of 3.1% for preoperative biliary drainage in pancreatic cancer. It is considered the optimal stent for preoperative biliary drainage in terms of the non‐RBO rate. UMIN Clinical Trial Registry (UMIN‐CTR 000041704).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DrainagePancreatic NeoplasmsJaundice, ObstructiveStentsHumansMaleFemaleAgedMiddle AgedProspective StudiesTreatment OutcomePreoperative CareAged, 80 and overPreoperative PeriodSafety

Stichwörter der Autor:innen

6‐mm metallic stentadverse eventsdistal malignant biliary obstructionpancreatic cancerpreoperative biliary drainage

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gastroenterology, University of Yamanashi Faculty of Medicine Graduate School of Medicine, Yamanashi, Japan.
  • Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Mie, Japan.
  • Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
  • Department of Gastroenterology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

ORCID-Profile: Shota Harai, Susumu Hijioka, Takeshi Ogura, Mitsuharu Fukasawa, Atsushi Okuda, Yusuke Ishida, Takehiko Koga, Yasuhito Tanaka, Daiki Yamashige

Förderung

  • National Cancer Center Research and Development Fund
  • Japanese Foundation for Research and Promotion of Endoscopy

Zitieren

APA

Harai, S., Hijioka, S., Yamada, R., Ogura, T., Fukasawa, M., Okuda, A., Horike, H., Inoue, D., Sekine, M., Ishida, Y., Koga, T., Kitamura, H., Tanaka, Y., Yoshinari, M., Kobayashi, K., Chatto, M., Yamashige, D., Kawasaki, Y., Nagashio, Y., & Okusaka, T. (2024). Safety of biliary drainage with 6‐mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY. Journal of Gastroenterology and Hepatology, 39(7), 1442-1449. https://doi.org/10.1111/jgh.16524

Vancouver

Harai S, Hijioka S, Yamada R, Ogura T, Fukasawa M, Okuda A, et al. Safety of biliary drainage with 6‐mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY. Journal of Gastroenterology and Hepatology. 2024;39(7):1442-1449. doi:10.1111/jgh.16524

BibTeX
@article{Harai2024,
  author = {Harai, Shota and Hijioka, Susumu and Yamada, Reiko and Ogura, Takeshi and Fukasawa, Mitsuharu and Okuda, Atsushi and Horike, Hideyuki and Inoue, Dai and Sekine, Masanari and Ishida, Yusuke and Koga, Takehiko and Kitamura, Hidetoshi and Tanaka, Yasuhito and Yoshinari, Motohiro and Kobayashi, Katsumasa and Chatto, Mark and Yamashige, Daiki and Kawasaki, Yuki and Nagashio, Yoshikuni and Okusaka, Takuji},
  title = {Safety of biliary drainage with 6‐mm metallic stent for preoperative obstructive jaundice in pancreatic cancer: PURPLE SIX STUDY},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  volume = {39},
  number = {7},
  pages = {1442--1449},
  doi = {10.1111/jgh.16524}
}
Kostenlos starten →